Psoriasis

LP0160-1510 COBRA
Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab
Studie ist initiiert; Rekrutierung: offen

M-14745-41 TRANSITION
An open-label, randomized, Phase IV study, to assess the efficacy and safety of Tildrakizumab in patients with moderate to severe
chronic plaque psoriasis who are non-responders to Dimethyl Fumarate (DMF) therapy
Studie läuft; Rekrutierung: offen

PROTOSTAR - CNTO1959PSO3011
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects >6 to 18 Years of Age
Studie läuft; Rekrutierung: offen

METABOLYX - CAIN457AD08
Eine randomisierte, multizentrische, 28-wöchige Studie zum Vergleich der Wirksamkeit und Sicherheit einer kombinierten Behandlung mit Cosentyx (Sekukinumb) und einer begleitenden Lebensstil-Intervention mit einer Cosentyx (Sekukinumab) Behandlung alleine bei erwachsenen Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis und gleichzeitig vorlieghendem Metabolischen Syndrom, gefolgt von einer 28-wöchigen Extensionphase.
Studie läuft, Rekrutierung offen

ABY-035-002 AFFIBODY
Eine Phase II, randomisierte, Parallelgruppen-, Placebo-kontrollierte, doppelblinde, Dosis-Findungsstudie zur Beurteilung der Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von ABY-035 in Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis
Studie läuft, Rekrutierung geschlossen

M16-178
A Randomized, Controlled, Multicenter, Open Label Study with Blinded Assessment of the Eficacy of the Humanized Anti-IL-23p19 Risankizumab Compared to FUMADERM in Subjects with Moderate to Severe Plaque Psoriasis Who are Naive to and Candidates for Systemic Therapy
Studie abgeschlossen

POLARIS (CNTO1959PSO3008)
A Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm® initial/Fumaderm®) for adult patients with moderate to severe plaque psoriasis who are candidates for and naive to systemic treatment
24-wöchige randomisierte Vergleichsstudie
Studie geschlossen

I1F-EW-RHBZ
A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis who are Naïve to Systemic Treatment
Studie abgeschlossen

PRIME (CAIN457ADE06)
A 24-week, randomized, controlled, multicenter, open label study with blinded assessment of the efficacy ob subcutaneous secukinumab compared to Famaderm® in adults with moderate to severe plaque psoriasis
Studie abgeschlossen

KIFUderm Study -
A 2:1 randomized, double-blinded placebo-controlled study to evaluate the efficacy and safety fo Fumaderm^® in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris
Phase III Studie zur Wirksamkeit und Sicherheit einer oralen Fumarsäureester-Therapie über 52 Wochen
Studie abgeschlossen

JUNCTURE (CAIN456A2309)
A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonsztrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis
52-Wochen Phase III-Studie
Studie abgeschlossen

VB-201
A Randomized, Double-Blind, 24-Week, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Studie abgeschlossen

METOP
An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatment schedule
Phase III-Studie über 52 Wochen
Studie abgeschlossen

Letzte Aktualisierung:
07. Mai 2021